Medicaid Provider SpendingClaims paid 2018–2024 · HHS public file
Home › OH › Parma Heights › NPI 1467571976
Physician

Med Care Group INC

Med Care Group INC was paid $7.36M by Medicaid between Jan 2018 and Dec 2024, across 191 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 21% of everything it billed.

33Billing provider infoMED CARE GROUP INC
PARMA HEIGHTS, OH 44130
33aNPI1467571976assigned 03/28/2007
33bProvider typeInternal Medicine Physician
28Total paid$7.36M
24GClaims473,896
24DCodes billed191
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers

Next to other Internal Medicine Physician providers in Ohio

Rank by total paid#6 of 663
Median peer was paid$17K
This provider vs. median422×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

$0$200K$400K2018201920202021202220232024
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
YearClaimsPaid
201845,576$834K
201943,597$827K
202053,908$1.03M
202152,379$1.20M
202292,109$1.36M
2023122,909$1.49M
2024incomplete63,418$618K
Box 24 · Service lines

What it billed for

CodeServiceShareClaimsBene. recordsPaid
99214 Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity 21% 27,844 20,855 $1.55M
99213 Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity 12% 23,619 15,432 $905K
96365 Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour 8.0% 12,866 5,174 $590K
96375 Therapeutic injection; each additional sequential IV push 7.6% 13,023 4,767 $556K
99051 4.5% 17,747 13,639 $329K
86769 4.4% 8,366 3,746 $327K
87811 Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) 4.1% 7,603 6,613 $299K
96374 Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance 3.3% 7,605 3,170 $245K
99204 Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity 2.7% 2,692 2,476 $198K
99203 Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity 2.6% 3,769 3,592 $194K
G2023 Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source 2.2% 8,510 7,437 $165K
99401 1.9% 7,418 6,073 $137K
179 more codes
80305 1.7% 14,369 $124K
G0108 Diabetes outpatient self-management training services, individual, per 30 minutes 1.6% 3,945 $120K
J3490 Unclassified drugs 1.4% 8,985 $106K
96372 Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular 1.0% 4,942 $76K
83880 <1% 3,224 $73K
87804 Infectious agent antigen detection by immunoassay; Influenza, each type <1% 5,565 $63K
96361 Intravenous infusion, hydration; each additional hour <1% 3,988 $52K
99406 <1% 5,917 $48K
83036 Hemoglobin; glycosylated (A1C) <1% 6,967 $46K
82306 Vitamin D; 25 hydroxy, includes fraction(s), if performed <1% 2,326 $43K
36415 Collection of venous blood by venipuncture <1% 20,499 $40K
93000 <1% 2,882 $40K
96360 Intravenous infusion, hydration; initial, 31 minutes to 1 hour <1% 1,253 $35K
80061 Lipid panel <1% 3,715 $35K
99442 <1% 978 $34K
80051 <1% 7,697 $33K
99050 <1% 2,183 $33K
85025 Blood count; complete (CBC), automated, and automated differential WBC count <1% 6,597 $33K
99202 Office or other outpatient visit for the evaluation and management of a new patient, straightforward <1% 907 $33K
99396 Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years <1% 525 $32K
84443 Thyroid stimulating hormone (TSH) <1% 2,957 $32K
87880 Infectious agent antigen detection by immunoassay; Streptococcus, group A <1% 2,468 $29K
82784 <1% 1,645 $29K
J2300 Injection, nalbuphine hydrochloride, per 10 mg <1% 6,776 $26K
82607 <1% 2,868 $26K
82565 <1% 7,788 $25K
84450 <1% 7,778 $25K
82310 <1% 7,780 $25K
82247 <1% 7,773 $24K
84460 <1% 7,791 $23K
82040 <1% 7,772 $23K
84075 <1% 7,762 $23K
82746 <1% 2,294 $20K
84520 <1% 7,787 $19K
87426 Infectious agent antigen detection, SARS-CoV-2 (COVID-19) <1% 709 $18K
J1885 Injection, ketorolac tromethamine, per 15 mg <1% 10,803 $18K
99395 Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years <1% 323 $18K
99212 Office or other outpatient visit for the evaluation and management of an established patient, straightforward <1% 659 $17K
84155 <1% 7,774 $17K
94640 Pressurized or nonpressurized inhalation treatment for acute airway obstruction <1% 2,055 $17K
94016 <1% 1,184 $15K
94010 <1% 911 $15K
83735 <1% 3,474 $14K
82552 <1% 1,575 $13K
84484 <1% 1,609 $12K
83874 <1% 1,634 $11K
J0696 Injection, ceftriaxone sodium, per 250 mg <1% 5,567 $10K
J7040 Infusion, normal saline solution, sterile (500 ml = 1 unit) <1% 4,730 $10K
96127 <1% 2,741 $10K
J3420 Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg <1% 6,764 $10K
96366 Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour <1% 721 $9K
90471 Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine <1% 473 $8K
83550 <1% 1,463 $8K
99201 <1% 404 $8K
J1100 Injection, dexamethasone sodium phosphate, 1 mg <1% 8,259 $7K
99441 <1% 294 $7K
83540 <1% 1,675 $7K
82550 <1% 1,568 $6K
80053 Comprehensive metabolic panel <1% 751 $6K
94060 <1% 123 $5K
99223 Prolong inpt eval add15 m <1% 98 $5K
85049 <1% 2,173 $4K
0001A <1% 47 $4K
J3475 Injection, magnesium sulfate, per 500 mg <1% 3,801 $4K
J0456 Injection, azithromycin, 500 mg <1% 1,662 $4K
82728 <1% 473 $4K
81003 <1% 2,246 $4K
90674 <1% 149 $3K
86703 <1% 490 $3K
J2550 Injection, promethazine hcl, up to 50 mg <1% 1,646 $3K
J7050 Infusion, normal saline solution, 250 cc <1% 7,940 $3K
82553 <1% 1,551 $3K
87807 <1% 364 $3K
99384 <1% 41 $3K
87491 Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe <1% 139 $3K
90688 <1% 206 $3K
J1200 Injection, diphenhydramine hcl, up to 50 mg <1% 3,770 $3K
G0396 Alcohol and/or substance (other than tobacco) misuse structured assessment (e.g., audit, dast), and brief intervention 15 to 30 minutes <1% 624 $3K
0003A <1% 35 $3K
99385 <1% 42 $3K
99233 Hospital visit by a doctor, follow-up day (complex) <1% 105 $3K
85041 <1% 2,052 $2K
96367 <1% 108 $2K
85014 <1% 2,168 $2K
J7030 Infusion, normal saline solution , 1000 cc <1% 1,418 $2K
85018 <1% 2,169 $2K
J2405 Injection, ondansetron hydrochloride, per 1 mg <1% 8,324 $2K
87591 Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe <1% 123 $2K
99394 Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) <1% 31 $2K
J1040 Injection, methylprednisolone acetate, 80 mg <1% 173 $2K
87905 <1% 242 $2K
J0131 Injection, acetaminophen, not otherwise specified,10 mg <1% 284 $2K
82043 <1% 308 $2K
G0472 Hepatitis c antibody screening, for individual at high risk and other covered indication(s) <1% 60 $1K
99211 Office or other outpatient visit for the evaluation and management of an established patient, minimal severity <1% 103 $1K
86677 <1% 167 $1K
83721 <1% 225 $1K
86780 <1% 176 $1K
J2930 Injection, methylprednisolone sodium succinate, up to 125 mg <1% 33 $1K
85048 <1% 2,071 $1K
Q0091 Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory <1% 42 $1K
86318 <1% 102 $1K
J1940 Injection, furosemide, up to 20 mg <1% 1,224 $1K
93923 <1% 14 $1K
0013A <1% 17 $1K
84436 <1% 455 $1K
83690 <1% 285 $1K
G0101 Cervical or vaginal cancer screening; pelvic and clinical breast examination <1% 39 $959.41
90715 <1% 26 $852.16
J3370 Injection, vancomycin hcl, 500 mg <1% 110 $807.01
S0028 Injection, famotidine, 20 mg <1% 3,842 $593.64
81025 <1% 124 $538.93
G0296 Counseling visit to discuss need for lung cancer screening using low dose ct scan (ldct) (service is for eligibility determination and shared decision making) <1% 27 $538.26
82150 <1% 291 $512.05
J2270 Injection, morphine sulfate, up to 10 mg <1% 239 $502.16
82947 <1% 112 $432.70
99239 Hospital discharge day management, more than 30 minutes <1% 13 $406.60
99238 Hospital discharge day management, 30 minutes or less <1% 15 $341.15
87899 <1% 132 $273.45
83718 <1% 224 $210.31
86580 <1% 34 $184.57
82465 <1% 199 $169.30
84478 <1% 225 $152.17
94375 <1% 136 $135.60
85380 <1% 14 $131.38
J7620 Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme <1% 1,387 $128.31
J3411 Injection, thiamine hcl, 100 mg <1% 27 $123.00
J2765 Injection, metoclopramide hcl, up to 10 mg <1% 105 $115.04
94664 <1% 18 $88.18
84550 <1% 29 $81.86
85007 <1% 28 $79.80
G0008 Administration of influenza virus vaccine <1% 14 $75.04
J7644 Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram <1% 446 $65.13
3044F <1% 189 $40.00
36416 <1% 12 $30.30
99408 <1% 277 $20.24
J1956 Injection, levofloxacin, 250 mg <1% 31 $12.43
J7042 5% dextrose/normal saline (500 ml = 1 unit) <1% 16 $7.90
J7613 Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg <1% 85 $5.56
G0442 Annual alcohol misuse screening, 5 to 15 minutes <1% 61 $2.83
J7614 Levalbuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 0.5 mg <1% 31 $0.40
91300 <1% 168 $0.32
3017F 0% 1,324 $0.00
G9902 Patient screened for tobacco use and identified as a tobacco user 0% 1,137 $0.00
G8420 Bmi is documented within normal parameters and no follow-up plan is required 0% 942 $0.00
G9906 Patient identified as a tobacco user received tobacco cessation intervention during the measurement period or in the six months prior to the measurement period (counseling and/or pharmacotherapy) 0% 525 $0.00
H0049 Alcohol and/or drug screening 0% 566 $0.00
3008F 0% 2,198 $0.00
1125F 0% 37 $0.00
1036F 0% 49 $0.00
94760 0% 35 $0.00
3079F 0% 151 $0.00
1111F 0% 2,359 $0.00
3075F 0% 124 $0.00
3080F 0% 184 $0.00
J7615 Levalbuterol, inhalation solution, compounded product, administered through dme, unit dose, 0.5 mg 0% 151 $0.00
91301 0% 22 $0.00
3074F 0% 157 $0.00
G9903 Patient screened for tobacco use and identified as a tobacco non-user 0% 62 $0.00
G9908 Patient identified as tobacco user did not receive tobacco cessation intervention during the measurement period or in the six months prior to the measurement period (counseling and/or pharmacotherapy) 0% 64 $0.00
G8950 Elevated or hypertensive blood pressure reading documented, and the indicated follow-up is documented 0% 34 $0.00
94761 0% 14 $0.00
J7616 0% 31 $0.00
4004F 0% 1,260 $0.00
G8417 Bmi is documented above normal parameters and a follow-up plan is documented 0% 340 $0.00
G0030 Patient screened for tobacco use and received tobacco cessation intervention during the measurement period or in the six months prior to the measurement period (counseling, pharmacotherapy, or both), if identified as a tobacco user 0% 180 $0.00
G8783 Normal blood pressure reading documented, follow-up not required 0% 1,280 $0.00
G8427 Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications 0% 2,001 $0.00
G8482 Influenza immunization administered or previously received 0% 692 $0.00
G9899 Screening, diagnostic, film, digital or digital breast tomosynthesis (3d) mammography results documented and reviewed 0% 176 $0.00
G8484 Influenza immunization was not administered, reason not given 0% 152 $0.00
G0444 Annual depression screening, 5 to 15 minutes 0% 72 $0.00
3077F 0% 235 $0.00
G8780 Counseling for diet and physical activity performed 0% 257 $0.00
G3002 Chronic pain management and treatment, monthly bundle including, diagnosis; assessment and monitoring; administration of a validated pain rating scale or tool; the development, implementation, revision, and/or maintenance of a person-centered care plan that includes strengths, goals, clinical needs, and desired outcomes; overall treatment management; facilitation and coordination of any necessary behavioral health treatment; medication management; pain and health literacy counseling; any necessary chronic pain related crisis care; and ongoing communication and care coordination between relevant practitioners furnishing care, e.g. physical therapy and occupational therapy, complementary and integrative approaches, and community-based care, as appropriate. required initial face-to-face visit at least 30 minutes provided by a physician or other qualified health professional; first 30 minutes personally provided by physician or other qualified health care professional, per calendar month. (when using g3002, 30 minutes must be met or exceeded.) 0% 75 $0.00
G9905 Patient not screened for tobacco use 0% 75 $0.00
3078F 0% 180 $0.00
H0050 Alcohol and/or drug services, brief intervention, per 15 minutes 0% 32 $0.00
99359 Prolong nursin fac eval 15m 0% 13 $0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialPOPA, CARMEN (OWNER)